c-Kit (Mast/stem cell growth factor receptor, SCFR or CD117) is a proteinthat in humans is encoded by the KIT gene.An essential cell surface marker for identifying specific kinds of hematopoietic (blood) progenitors in the bone marrow is called c-Kit (CD117). In addition to other cell types, hematopoietic stem cells express the cytokine receptor c-Kit on their surface. Some types of cancer may be linked to altered forms of this receptor. Stem cell factor is bound by the type III receptor tyrosine kinase known as c-Kit. To activate its intrinsic tyrosine kinase activity, c-Kit forms an adimer with stem cell factor (SCF). This adimer then phosphorylates and activates signal transduction molecules that spread the signal throughout the cell. Cell survival, division, and proliferation are affected by c-Kit signaling.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V109189 | (S)-c-Kit-IN-12 | 2797973-69-2 | (S)-c-Kit-IN-12 (compound 2b) is a potent c-Kit inhibitor with IC50 values of less than 10 nM against c-Kit in four KIT mutant cell models (BAF3 KIT EX11 DEL, EX11 DEL/D816H, EX11 DEL/T670I, and EX11 DEL/V654A). |
|
V77254 | Anti-Mouse CD117 Antibody | Anti-Mouse CD117 Antibody is an IgG2b antibody inhibitor against mouse CD117. | |
|
V3474 | AZD3229 | 2248003-60-1 | AZD3229 (AZD-3229) is a novel, potent, pan-KIT mutantinhibitor with anticancer activity. |
|
V4154 | AZD3229 Tosylate | 2248003-71-4 | AZD3229 Tosylate, the tosylate salt ofAZD-3229,is a novel, potent, pan-KIT mutantinhibitor with antitumor activity. |
|
V69291 | Bezuclastinib (CGT9486; PLX 9486) | 1616385-51-3 | Bezuclastinib (CGT9486; PLX 9486) is a potent inhibitor of c-kit and c-kit D816V, 0.0001 |
|
V120316 | c-Kit Receptor modulator-1 | 932401-20-2 | c-Kit receptor modulator-1 (compound #22) is a c-Kit receptor modulator. |
|
V22674 | ISCK03 | 945526-43-2 | ISCK03 is a potent c-kit inhibitor. |
|
V120281 | c-Kit-IN-10 | 1123512-36-6 | c-Kit-IN-10 (compound 1) is a c-Kit inhibitor. |
|
V120201 | c-Kit-IN-11 | 1185279-55-3 | c-Kit-IN-11 (compound A7) is a c-Kit inhibitor with an IC50 value of 76 nM against Mo7e cells. |
|
V109236 | c-Kit-IN-12 | 2797973-68-1 | c-Kit-IN-12 (compound 2a) is a potent c-Kit inhibitor with IC50 values of less than 10 nM against c-Kit in four KIT mutant cell models (BAF3 KIT EX11 DEL, EX11 DEL/D816H, EX11 DEL/T670I, and EX11 DEL/V654A). |
|
V109369 | c-Kit-IN-13 | 3041025-10-6 | c-Kit-IN-13 (compound I) is a c-kit kinase inhibitor. |
|
V110544 | c-Kit-IN-14 | 3041025-49-1 | c-Kit-IN-14 (compound 1) is a c-kit kinase inhibitor. |
|
V93685 | c-Kit-IN-6 | c-Kit-IN-6 (Compound 101) is a c-Kit inhibitor with IC50 values ranging from 100 nM to 1 μM. | |
|
V93129 | c-Kit-IN-8 | 2941024-89-9 | c-Kit-IN-8 (Compound 53) is an inhibitor of c-Kit kinase and inhibits uKIT kinase with IC50 > 1 μM. |
|
V116395 | CD117/c-Kit aptamer sodium | CD117/c-Kit sodium aptamer is a single-stranded DNA aptamer that targets CD117, a biomarker highly expressed in acute myeloid leukemia (AML) cells. | |
|
V116175 | CHMFL-KIT-031 | CHMFL-KIT-031 is a highly selective KIT V559D inhibitor with an IC50 value of 28 nM. | |
|
V3757 | DCC-2618 HCl | Ripretinib HCl (DCC2618; DCC-2618; Qinlock), the hydrochloride salt of DCC-2618, is an orally bioactive pan KIT and PDGFRA inhibitor approved in 2020 for the treatment of adults with advanced gastrointestinal stromal tumor. | |
|
V69295 | Elenestinib (BLU-263) | 2505078-08-8 | Elenestinib (BLU-263) is a potent orally bioactive tyrosine kinase inhibitor. |
|
V69296 | Elenestinib phosphate (BLU-263 phosphate) | 2832013-93-9 | Elenestinib phosphate (BLU-263 phosphate) is a potent orally bioactive tyrosine kinase inhibitor. |
|
V118789 | KIT A829P Recombinant Human Active Protein Kinase | KIT (CD117) is an important cell surface marker used to identify certain types of hematopoietic progenitor cells in the bone marrow. |